Clinical trial · Observational
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)
NCT02559804CI-TRIAL-00076037NB-SCIrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastic Tumors | Neuroblastic Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| survival and late effects | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients NB with SCI
- description
- Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
- interventionNames
- Other: survival and late effects
Primary outcomes (3)
- measure
- prevalence of neurologic consequences
- timeFrame
- for 5 years
- description
- American Spinal Injury Association ASIA impairment scale
- measure
- prevalence of orthopedic consequences
- timeFrame
- for 5 years
- description
- using Common Terminology Criteria for Adverse Events v. 4.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression) * No previous chemotherapy, except steroids, in the last 6 months * Age \<18 years * Minimal planned follow-up of 5 years * Parent/patient written informed consent (Appendix 1(A,B,C)) Exclusion Criteria: * Invasion of intervertebral foramina only
References
Publications (0)
Data not yet available
No reference posted for this study.